Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02779686 · ClinicalTrials.gov registry record
PIIR Study: Comparison of Genetic Tests for Age-Related Macular Degeneration
A clinical trial, sponsored by University of Missouri-Columbia.
- Terminated
- Registry status
- 32
- Enrollment target
NCT02779686: Clinical Trial study, sponsored by University of Missouri-Columbia.
NCT02779686 is a clinical trial that was terminated before completion, run by University of Missouri-Columbia. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02779686 was terminated before completion, sponsored by University of Missouri-Columbia.
- TERMINATED
- Registry status
- 32 participants
- Enrollment target
Study Summary
This study is being conducted to compare two different genetic tests developed to determine an individuals risk of developing serious vision threatening complications from age-related macular degeneration (ARMD).
Primary Outcome
Risk score assigned after genetic analysis of a buccal swab by the RetnaGene (Sequenom) genetic test.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2012-01 |
| Est. Completion | 2012-12 |
Why NCT02779686 stopped before completion
NCT02779686 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 32 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02779686 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02779686 about?
NCT02779686 is a clinical study titled "PIIR Study: Comparison of Genetic Tests for Age-Related Macular Degeneration". This study is being conducted to compare two different genetic tests developed to determine an individuals risk of developing serious vision threatening complications from age-related macular degeneration (ARMD).
What is the current status of trial NCT02779686?
This trial is currently terminated. The enrollment target is 32 participants. The study started on 2012-01. Estimated completion is 2012-12.
Who is sponsoring clinical trial NCT02779686?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia